Key result
Structural heart disease linked to ~104% higher 1-year mortality risk after SVT ablation.
Why the study?
The study aimed to compare patient characteristics, safety, and efficacy of catheter ablation of SVT in patients with versus without structural heart disease.
Does the presence of structural heart disease affect the safety and efficacy of catheter ablation for supraventricular tachycardia?
Observational (n=12,536)
Yes
Does the presence of structural heart disease affect the safety and efficacy of catheter ablation for supraventricular tachycardia?
Hazard Ratio: 2.04 (95% CI 1.45–2.87)
Absolute Event Rate: 2.6% vs 0.7%
p-value: p=<0.001
Catheter ablation for supraventricular tachycardia is safe and effective in patients with structural heart disease, with periprocedural complication rates comparable to those without structural heart disease.
Structural heart disease signals higher post-ablation mortality in SVT; leaves open whether ablation or comorbidities drive excess risk.
AIM: To compare patient characteristics, safety and efficacy of catheter ablation of supraventricular tachycardia (SVT) in patients with and without structural heart disease (SHD) enrolled in the German ablation registry. METHODS AND RESULTS: From January 2007 until January 2010, a total of 12,536 patients (37.2% with known SHD) were enrolled and followed for at least one year. Patients with SHD more often underwent ablation for atrial flutter (45.8% vs. 20.9%, p < 0.001), whereas patients without SHD more often underwent ablation for atrioventricular nodal reentrant tachycardia (30.2% vs. 11.8%, p < 0.001) or atrioventricular reentrant tachycardia (9.1% vs. 1.6%, p < 0.001). Atrial fibrillation catheter ablation procedures were performed in a similar proportion of patients with and without SHD (38.1% vs. 36.9%, p = 0.21). Overall, periprocedural success rate was high in both groups. Death, myocardial infarction or stroke occurred in 0.2% and 0.1% of patients with and without SHD (p = 0.066). Major non-fatal complications prior to discharge were rare and did not differ significantly between patients with and without SHD (0.5% vs. 0.4%, p = 0.34). Kaplan-Meier mortality estimate at 1 year demonstrated a significant mortality increase in patients with SHD (2.6% versus 0.7%; p < 0.001). CONCLUSION: Patients with and without SHD undergoing SVT ablation exhibit similar success rates and low major complication rates, despite disadvantageous baseline characteristics in SHD patients. These data highlight the safety and efficacy of SVT ablation in patients with and without SHD. Nevertheless Kaplan-Meier mortality estimates at 1 year demonstrate a significant mortality increase in patients with SHD, highlighting the importance of treating the underlying condition and reliable anticoagulation if indicated.
No takes yet. Share an insight, caveat, or question.
Eitel et al. (2021) conducted an observational in Supraventricular tachycardia (SVT) (n=12,536). Structural heart disease (SHD) vs. No structural heart disease was evaluated on 1-year all-cause mortality (adjusted HR 2.04, 95% CI 1.45-2.87, p=<0.001). In patients undergoing catheter ablation for supraventricular tachycardia, the presence of structural heart disease independently increased the risk of 1-year mortality compared to patients without structural heart disease (adjusted HR 2.04).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: